Financial Performance & Divestment - HUTCHMED reported profits of $455 million in H1 2025, driven by a $477.5 million gain from the partial divestment of SHPL[15] - The company divested a 45% equity interest in SHPL, retaining 5%, resulting in gross proceeds of $609 million[13] - HUTCHMED's cash, cash equivalents, and short-term investments totaled $1,364.5 million as of June 30, 2025[12] - Oncology revenue was $143.5 million in H1 2025, a decrease from $168.7 million in H1 2024[15] - The company revised its 2025 Oncology Revenue Guidance to $270 million - $350 million, down from the previous guidance of $350 million - $450 million[20] Commercial Product Performance - FRUZAQLA® in-market sales grew by 25% to $162.8 million in H1 2025[10, 22] - ELUNATE® in-market sales decreased by 29% to $43.0 million in H1 2025[22] - ORPATHYS® in-market sales decreased by 41% to $15.2 million in H1 2025[22] - SULANDA® in-market sales decreased by 50% to $12.7 million in H1 2025[22] Pipeline & Development - The company is developing an Antibody-Targeted Therapy Conjugate (ATTC) platform with multiple drug candidates, with the first candidate US + China clinical trial initiation expected in H2 2025[10] - Savolitinib received China NMPA approval in June 2025 for 2L NSCLC MET amplification[10, 36, 46]

Safe harbor statement & disclaimer R&D UPDATES October 31, 2025 HKEX: 13, Nasdaq / AIM:HCM The performance and results of operations of the HUTCHMED Group contained within this presentation are historical in nature, and past performance is no guarantee of future results. The performance and results of operations of the Group contained within this presentation are historical in nature, and past performance is no guarantee of future results of the Group. This presentation contains forward-looking statements w ...